Brooks Lab Peer Comparison

NSE: BROOKS | BSE: 533543

₹69.28

₹3.29 (4.99%)

As on 28-Aug-2026IST

Market cap

₹205 Cr

Revenue (TTM)

₹83 Cr

P/E Ratio

15.5

P/B Ratio

1.7

Div. Yield

0 %

Edit

	Brooks Lab	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Market cap (₹ Cr)	205	21,501	19,125	18,253	17,766
Revenue (₹ Cr)	83	2,570	2,287	3,230	2,432
Net Profit (₹ Cr)	4.57	735.15	678.07	666.92	169.62
Net Margin (%)	5.42	26.88	28.10	20.60	6.90
RoE (%)	11.09	19.16	19.73	18.75	20.76
Price to Earnings	15.50	29.25	28.74	28.35	104.74
Price-To-Book	1.65	4.88	5.08	4.51	19.65

Income Statement (₹ Cr)

	Brooks Lab	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Operating Revenue	85.74	2,519.65	1,937.47	2,893.64	2,275.58
Total Income	86.91	2,707.60	2,033.90	2,912.00	2,304.07
Total Expenditure	78.68	1,615.47	1,290.54	1,876.44	2,013.55
EBITDA	7.06	904.18	646.93	1,017.20	262.03
Depreciation	1.59	57.73	65.96	315.46	28.58
EBIT	5.47	846.45	580.97	701.74	233.45
Interest	0.84	9.57	0.61	231.29	4.49
Other Income	1.17	187.95	96.43	18.36	28.49
Exceptional Items	--	-49.16	--	--	-5.25
Profit before Tax	24.58	975.67	676.78	488.87	252.20
Provision for Tax	0.18	253.24	135.69	114.20	64.68
Profit after Tax	24.58	722.43	541.09	374.67	187.52

	Brooks Lab	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Shareholder's Funds	122.66	4,202.90	2,850.49	2,854.36	872.79
Minority Interest	--	--	35.90	417.40	--
Non-Current Liabilities	3.70	19.19	13.24	2,100.97	394.49
Current Liabilities	21.81	627.48	305.99	1,489.55	1,109.50
Total Liabilities	148.17	4,921.88	3,207.85	6,862.28	2,414.58

	Brooks Lab	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Non-Current Assets	110.76	1,046.35	1,071.67	5,531.13	509.16
Current Assets	37.42	3,803.22	2,133.95	1,331.15	1,859.88
Total Assets	148.17	4,921.88	3,207.85	6,862.28	2,414.58
Total Debt*	7.28	2.50	0.55	2,421.66	0.00
Net Current Assets	15.60	3,175.74	1,827.96	-158.40	750.38
Contingent Liabilities	122.94	370.49	0.64	64.29	121.23

	Brooks Lab	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Cash From Operating Activities	9.29	967.57	432.37	1,065.01	-15.14
Cash Flow from Investing Activities	-2.92	-561.67	-334.73	-79.97	18.69
Cash from Financing Activities	0.17	-798.31	-38.32	-881.32	-91.97
Net Cash Inflow / Outflow	6.54	-392.41	59.32	103.72	-88.42

	Brooks Lab	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
ROCE (%)	21.72	23.39	26.22	13.59	31.24
ROE (%)	22.27	17.16	21.72	13.81	23.02
ROA (%)	18.08	14.91	18.37	5.48	8.90
EBIT Margin (%)	9.60	43.34	38.37	35.79	12.77
Net Margin (%)	28.29	26.68	26.60	12.87	8.14
Cash Profit Margin (%)	30.53	29.72	31.33	23.22	9.47

	Brooks Lab	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Revenue Growth (%)	3.85	10.45	14.37	44.02	32.59
EBIT Growth (%)	41.36	19.68	20.21	48.22	-1.38
Net Profit Growth (%)	346.65	-5.88	17.27	-5.65	62.02
EPS Growth (%)	346.65	-5.88	17.25	-10.39	62.02
Book Value Growth (%)	25.03	-0.34	23.77	10.19	13.51

	Brooks Lab	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Price / Earnings	4.49	29.89	28.38	54.83	103.45
Price / Book Value	0.90	5.14	5.52	6.78	22.39
Dividend Yield (%)	0.00	1.59	0.30	0.52	0.46
EV/EBITDA	13.39	16.93	19.78	20.75	65.23
Market Cap (₹ Cr)	110.43	21,592.90	15,219.80	19,292.77	19,398.64

	Brooks Lab	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debt to Equity	0.06	0.00	0.00	0.85	0.00
Short term debt to equity ratio	0.05	0.00	0.00	0.14	--
Current Ratio	1.72	6.06	6.97	0.89	1.68
Quick Ratio	1.21	5.31	5.88	0.67	0.75
Interest Coverage	30.43	102.95	1,110.48	3.11	57.17

	Brooks Lab	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debtors to sales (%)	18.80	7.22	32.65	15.85	9.39
Asset Turnover	0.63	0.54	0.66	0.43	1.08
Receivable days	76.86	26.06	110.70	54.07	31.88
Inventory Days	43.05	65.95	65.86	32.16	126.03
Payable days	89.64	81.01	105.88	140.91	163.79
Cash Conversion Cycle	30.27	11.00	70.68	-54.68	-5.88

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.